Patents by Inventor Mark S. Dennis

Mark S. Dennis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10865251
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: December 15, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Publication number: 20200369746
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, Fc dimers and fusion proteins comprising such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 5, 2020
    Publication date: November 26, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Patent number: 10808036
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 20, 2020
    Assignee: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Publication number: 20200317749
    Abstract: The present disclosure relates to albumin variants, derivatives and analogs thereof. In particular, provided are albumin variants that bind with increased efficiency to FcRn, including albumin variants that bind with increased efficiency at low pH levels but inefficiently or not at all at neutral pH levels. The albumin variants, derivatives, and analogs have an increased serum half-life when compared to naturally-occurring albumins.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 8, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Mark S. Dennis, Mihalis Kariolis, Adam Silverman
  • Publication number: 20200299408
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 24, 2020
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU
  • Publication number: 20200299409
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 24, 2020
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, Jr., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU
  • Publication number: 20200289627
    Abstract: Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 17, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200277584
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 3, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Mark S. DENNIS, Jennifer A. GETZ, Anastasia HENRY, Mihalis KARIOLIS, Cathal MAHON, Adam P. SILVERMAN, Ankita SRIVASTAVA, Julie ULLMAN, Junhua WANG, Joy Yu ZUCHERO
  • Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200216522
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 9, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • Publication number: 20200123267
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Publication number: 20200113624
    Abstract: The disclosure provides a method of manufacturing a flexible circuit electrode assembly and an apparatus manufactured by said method. According to the method, an electrically conductive sheet is laminated to an electrically insulative sheet. An electrode is formed on the electrically conductive sheet. An electrically insulative layer is formed on a tissue contacting surface of the electrode. The individual electrodes are separated from the laminated electrically insulative sheet and the electrically conductive sheet. In another method, a flexible circuit is vacuum formed to create a desired profile. The vacuum formed flexible circuit is trimmed. The trimmed vacuum formed flexible circuit is attached to a jaw member of a clamp jaw assembly.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Inventors: Barry C. Worrell, David C. Yates, Joseph D. Dennis, Mark A. Davison, Geoffrey S. Strobl
  • Patent number: 10555769
    Abstract: The disclosure provides a method of manufacturing a flexible circuit electrode assembly and an apparatus manufactured by said method. According to the method, an electrically conductive sheet is laminated to an electrically insulative sheet. An electrode is formed on the electrically conductive sheet. An electrically insulative layer is formed on a tissue contacting surface of the electrode. The individual electrodes are separated from the laminated electrically insulative sheet and the electrically conductive sheet. In another method, a flexible circuit is vacuum formed to create a desired profile. The vacuum formed flexible circuit is trimmed. The trimmed vacuum formed flexible circuit is attached to a jaw member of a clamp jaw assembly.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: February 11, 2020
    Assignee: Ethicon LLC
    Inventors: Barry C. Worrell, David C. Yates, Joseph D. Dennis, Mark A. Davison, Geoffrey S. Strobl
  • Patent number: 10508151
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: December 17, 2019
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Publication number: 20190274291
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 12, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • Publication number: 20190270794
    Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
    Type: Application
    Filed: October 27, 2017
    Publication date: September 5, 2019
    Inventors: David Holtzman, Hong Jiang, Fan Liao, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
  • Patent number: 10343634
    Abstract: An apparatus includes a vehicle structure, a bumper, an elongate structural member, and an extension portion. The elongate structural member is able to crush longitudinally in response to application of force in a longitudinal direction. The extension portion is able to crush longitudinally in response to application of force in the longitudinal direction, is connected to the elongate structural member such that the elongate structural member and the extension portion support the bumper with respect to the vehicle structure, and is operable to move the bumper between an extended position and a retracted position with respect to the vehicle structure to change a distance between the bumper and the vehicle structure.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Apple Inc.
    Inventors: Erik Mikael Fermer, Alice C. Watts, Joel Frederic Jensen, Ronald Jack Smith, Mark B. Rober, Sung Hoon Kim, David Jennings Dostal, Russell Cranstoun Mead, Jr., Todd Elliot Lewis, Jesse T. Buehler, Nathaniel J. Dennis, Tommaso P. Rivellini, Robert R. Mayer, Anthony S. Montevirgen, Donald J. Parr, Bryce A. Woollard, Adam J. Golman, Kevin P. Makowski, Daniel E. Rivera